Q&A

Should we welcome the coming wave of anti-obesity drugs, and what’s at stake in the argument over the 14-day limit on embryo research?

Our final Q&A episode of the year tackles two medical ethics questions in the news recently. The first is Wegovy, the ground-breaking anti-obesity drug which has been a controversial sensation in the United States. It is now available (in very limited supply) on the NHS here in the UK, but only for those with quite serious obesity with BMIs of 35 or higher. Should Christians hail this a brilliant medical advance tackling a serious public health issue, or a worrying example of big pharma trying to medicate away our self-control? Next, we discuss a new push by some scientists to soften the ground ahead of a campaign to extend the current 14-day limit on human embryo research. Why do researchers want to keep embryos alive in petri dishes for longer, and will it actually benefit any of us in the end really?

Listen to other episodes of Matters of Life and Death or find us on Spotify, Apple Podcasts, Pocket Casts, Google Podcasts, Podcast Addict, Castbox or whatever app you use to subscribe and receive new episodes sent straight to your device.

Tags
Most read posts
What can we learn from how the early church lived out their faith during their own pandemics?
Navigating the transitions of later life
How are young people different to those who came before, and what can we learn from them?
Living faithfully as we approach retirement, dependence, dementia and death
Investing in the next generation - Lessons from John Stott and others
Recent posts
There may be no straightforward way to turn around a struggling health service
Assisted suicide: Euthanasia tourism takes off in the US amid fresh push to change law in Britain
Innocence and guilt, partial evidence, and living with unknowns
Capacities, calling, relationships - disentangling this foundational theological tenet
The long and sad history of medical trial scandals gains another sobering chapter